CAS: 621-63-6; 2,2-Diethoxyethanol

上下游产品

CAS号6065-82-3 二乙氧基乙酸乙酯 | CAS号60468-85-1 acetoxyacetalde... | CAS号2032-35-1 2-溴-1,1-二乙氧基乙烷 | CAS号621-62-5 氯乙醛缩二乙醇 | CAS号103410-71-5 acetic acid,1,2... | CAS号5344-23-0 2,2-二乙氧基乙醛 | CAS号105-57-7 1,1-二乙氧基乙烷 | CAS号51806-20-3 1,1-Diethoxy-2-... | CAS号42783-78-8 苄氧基乙醛缩二乙醇 | CAS号3975-14-2 1,1,2,2-Tetraet... | CAS号107646-10-6 1,1-diethoxybut... | CAS号101268-52-4 2,2-二乙氧基乙基 苯甲酸 | CAS号42783-78-8 苄氧基乙醛缩二乙醇 | CAS号2488-95-1 β-羟乙基乙二胺 | CAS号141-46-8 羟乙醛 | CAS号64-17-5 乙醇 | CAS号7148-78-9 肉桂醛二乙缩醛 | CAS号32091-51-3 3H-噁唑-2-硫酮 | CAS号67210-05-3 glycolaldehyde ... | CAS号7038-14-4 1,1,2-tris(ethy...

2-溴-1,1-二乙氧基乙烷置于乙醚,氨,Sodium,Xylene体系中,化学反应生成 2,2-二乙氧基乙醇
参考文献:Heterocyclic Vinyl Ethers. X. Dialkoxy 1,4-Dioxanes And Alkoxy 1,4-Dioxenes1
标题:Heterocyclic Vinyl Ethers. X. Dialkoxy 1,4-Dioxanes And Alkoxy 1,4-Dioxenes1
摘要:
DOI:10.1021/ja01628A108

专利信息

专利号:US-5139940-A
优先权日:1989-10-26
标题 :Activation compounds and methods of synthesis of activation compounds
发明人：ISAACS STEPHEN T; CIMINO GEORGE D; METCHETTE KENNETH C; TESSMAN JOHN W
权利人:ISAACS STEPHEN T; CIMINO GOERGE D; METCHETTE KENNETH C; TESSMAN JOHN W
摘要:The invention is directed to isopsoralen compound compositions that contain a variety of substitutions which yet permit their binding to nucleic acid polymers. Reaction conditions that activate these bound isopsoralens results in covalent crosslinking to the nucleic acid polymers. The resultant complex is inhibited from being a template for the template-directed enzymatic synthesis of a complementary nucleic acid polymer. Beside the isopsoralens compositions, the invention includes their synthesis, the nucleic acid complex production and detection, and the above inhibitory method of use of the isopsoralens.

专利号:US-2003162992-A1
优先权日:2001-12-14
标 题 :Preparation of intermediates useful in the synthesis of antiviral nucleosides
发明人：WATANABE KYOICHI A; DU JINFA
摘要:The present invention is an efficient process for the manufacture of α-acyloxyacetaldehyde, a key intermediate in the synthesis of 1,3-oxathiolane and 1,3-dioxolane nucleosides.

专利号:US-2012136015-A1
优先权日:2009-04-13
标题:Process for preparation of endothelial receptor antagonist (bosentan)
发明人：JOSHI SHREERANG; KHAN RASHID; BENDRE DEVEN; SALUNKHE DADASAHEB; GUDEKAR SANKET
权利人:JOSHI SHREERANG; KHAN RASHID; BENDRE DEVEN; SALUNKHE DADASAHEB; GUDEKAR SANKET; SANDOZ AG
摘要:The present invention relates to processes for the preparation of an endothelial receptor antagonist. The present invention particularly relates to synthesis of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzene sulfonamide (bosentan).

专利号:WO-9925689-A1
优先权日:1997-11-14
标题 :Process for the preparation of acetal derivatives of 1,4-dihydropyridines
发明人：KARUP GUNNAR LEO; PREIKSCHAT HERBERT FRITZ; PEDERSEN SOEREN BOLS
权利人:GEA FARMACEUTISK FABRIK AS; KARUP GUNNAR LEO; PREIKSCHAT HERBERT FRITZ; PEDERSEN SOEREN BOLS
摘要:A process for the preparation of 1,4-dihydropyridine acetal derivatives of formula (II) wherein R1 each, independently, represents H, Cl or CF¿3; R?2 represents H, C¿1?-C5 alkyl, C3-C6 cycloalkyl or aralkyl; R?3 and R4¿ which may be the same or different, represent C¿1?-C5 alkyl, C3-C6 cycloalkyl, aralkyl or together represent -(CH2)m-, wherein m is 2 or 3, and n is 1 or 2, wherein the 1,4-dihydropyridine ring structure is formed by a Hantzsch synthesis carried out in one or more steps using a compound containing a group of formula (a); wherein R?3 and R4¿ have the same meanings as defined above, as one of the reactants in the Hantzsch condensation, is described. The Hantzsch synthesis, or at least one step thereof, is carried out in a solvent, which is capable of forming an azeotrope with water, under azeotropic removal of water of reaction. The compounds of formula (II) are useful as intermediates for the preparation of pharmaceutically active 1,4-dihydropyridines and other intermediates of use for such purpose.

专利号:US-2013053258-A1
优先权日:2010-03-22
标题:Combinatorial library, a method for preparation of that combinatorial library, a method for sequence identification, a method for sequencing the elements of combinatorial libraries of oligonucleotides and/or oligonucleotide analogues, the use of a linker to generate combinatorial libraries and a sequence identification set
发明人：MARKIEWICZ WOJCIECH T; RULKA ANNA
权利人:MARKIEWICZ WOJCIECH T; RULKA ANNA; INST CHEMII BIOORG PAN
摘要:The invention provides a combinatorial library, a method for preparation of that combinatorial library, a method for sequence identification, a method for sequencing the elements of combinatorial libraries of oligonucleotides and/or oligonucleotide analogues, the use of a linker to generate combinatorial libraries and a sequence identification set. More precisely, the objective of the invention is the ability to “readâ€? sequences of selected elements of combinatorial libraries of freely modified synthetic oligonucleotides. The solution may be used both for researching for leading compounds in the pharmaceutical industry, and as a tool for studying the properties of oligonucleotides in the aspect of their potential use in experimental antisense or antigen therapy. The invention develops an appropriate strategy for determining the structure of isolated library elements, as usefulness of the combinatorial library depends on the ability to recognize the structure of its elements. Thanks to the developed and presented method for sequencing combinatorial oligonucleotide libraries it is possible to indisputably identify the sequences of biologically active elements selected by the combinatorial synthesis ethod.

专利号:WO-2006079916-A1
优先权日:2005-01-26
标 题 :Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
发明人：ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; RAHMAN HAYAT; SCHWEITZER BARBARA ANN; TENBRINK RUTH ELIZABETH
权利人:PHARMACIA & UPJOHN CO LLC; ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; RAHMAN HAYAT; SCHWEITZER BARBARA ANN; TENBRINK RUTH ELIZABETH
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.